| Acquired by | Boston Scientific |
| Date | 11/10 |
| Terms | Cash and Stock |
| Website | sadramedical.com |
| Blog | sadramedical.com/... |
| Category | BioTech |
| Employees | |
| Founded | 2003 |
| Description | Aortic Valve Disease Therapy Innovator |
| TOTAL | $58M |
| FUNDING TOTAL | $58M |
| Series A, 6/04 Pequot Capital ONSET Ventures Schroder Ventures | $9M |
| Series B, 10/06 Oakwood Medical Investors Pequot Capital ONSET Ventures SV Life Sciences Boston Scientific | $19M |
| Series C, 5/09 Accuitive Medical Ventures Boston Scientific Finistere Ventures FirstMark Capital ONSET Ventures SV Life Sciences Oakwood Medical Investors | $30M |
Sadra Medical is exploring new minimally invasive alternatives to traditional surgical valve replacement. The company hopes that devices allowing such procedural advances will facilitate and enhance treatment of aortic valve disease.
Sadra Medical is dedicated to developing innovative new therapies for the treatment of aortic valve disease. By developing minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients. Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in U.S. have aortic valve stenosis; however, only a small percentage of those are treated with the current standard of care, valve replacement during open-heart surgery using cardiopulmonary bypass. By developing a highly effective aortic valve replacement that is designed to reduce the risks and morbidity associated with open surgical valve replacement, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today.
Sadra Medical, a subsidiary of Boston Scientific.
